February 2021 Issue of The Medicine Maker

Is the European Union better prepared for future healthcare crises?

How can we get macromolecules across the intestinal epithelial barrier?

New EU “transparency” measures give member states the power to block vaccine exports if manufacturers can’t meet contractual obligations.

Mice with severed spinal cords walk again after gene therapy.

With the right partner to help you harness the many benefits, nasal delivery is not to be sniffed at.

Pharma hasn’t always covered itself in glory – but as the world scrambles for viable COVID-19 interventions, it has a rare opportunity to rebrand.

Vectura has more than 20 years’ experience in helping customers bring inhaled medicines to the market.

What role have small molecules played in the fight against COVID-19?

Experts from our previous Power Lists discuss the challenges of leadership during these trying times.

The increasing complexity of biologics raises significant manufacturing challenges – not least regarding cost control and downstream purification.

Ewoud van Tricht explores three novel methods that could streamline the development of adenovirus vaccines for COVID-19 at Janssen.

Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.

Cell and gene therapy manufacturing technologies and methods are advancing rapidly, but can regulators keep up?

US Army combat veteran Luis Alvarez has developed a new drug delivery technology that can convert recombinant proteins into material-binding variants.

We Sit Down With Sandy Macrae, Chief Executive Officer, Sangamo Therapeutics, USA.